Testing

Meera Sridharan, M.D., Ph.D., explains Mayo Clinic Labs’ testing approach for atypical hemolytic uremic syndrome (aHUS). The serological complement panel examines nine analytes to gain a thorough understanding of the complement cascade to confirm diagnosis and direct care.

In April 2021, Mayo Clinic Laboratories announced two new tests along with numerous reference value changes, obsolete tests, and algorithm changes.

Mayo Clinic Laboratories now offers a noninvasive approach for the molecular detection of H. pylori, with results that include prediction of clarithromycin resistance delivered within 24 hours.

The following list includes updates posted to mayocliniclabs.com during the month of April.

Andrew McKeon, M.B., B.Ch., M.D., discusses updates that are being made to Mayo Clinic Laboratories' autoimmune profile that will remove some antibodies from those profiles. He describes the rationale behind the updates, reviews which antibodies are involved, and explains how the changes will streamline testing and enhance test interpretation.

Christopher Klein, M.D., discusses Mayo Clinic’s updated myasthenia gravis and Lambert-Eaton syndrome testing approach. Automatic reflex to second-line testing saves time and increases sensitivity and specificity to confirm diagnosis in patients with atypical presentation.

The following list includes updates posted to mayocliniclabs.com during the month of March.

In February 2021, Mayo Clinic Laboratories announced three new tests along with numerous reference value changes, obsolete tests, and algorithm changes.

The following list includes updates posted to mayocliniclabs.com during the month of February.

Andrew McKeon, M,B., B.Ch., M.D., provides an overview of Mayo Clinic Laboratories' new paraneoplastic vision loss evaluation — a test that can help direct a cancer diagnosis and guide treatment. He reviews why this test was developed, when it should be ordered, and how the results can affect patient care.

In January, Mayo Clinic Laboratories announced a new test along with numerous reference value changes, obsolete tests, and algorithm changes.

Being able to identify SARS-CoV-2 in tissue is key to better understand the virus that causes COVID-19. Now, a first-of-its-kind test that detects SARS-CoV-2 in formalin-fixed, paraffin-embedded tissue is available from Mayo Clinic Laboratories.

The following list includes updates posted to mayocliniclabs.com during the month of January.